Clinical research projects related to antibacterial resistance (AR) focus on a variety of approaches, including evaluating the safety and effectiveness of new antimicrobial therapeutics, and developing novel prevention strategies. In addition, NIAID supports a number of studies on optimizing use of existing drugs. An important goal of this research is to identify treatment regimens that limit the emergence of drug resistance, which is a growing problem in treating infectious diseases. View related NIAID news releases.
Select examples of NIAID-supported AR clinical research activities are listed below. These include ongoing and recently supported trials and studies in development. View definitions of study phases and other words related to clinical research.
In 2013, NIAID launched the Antibacterial Resistance Leadership Group (ARLG), a major new clinical effort to address AR and complement other ongoing AR clinical research activities. The ARLG has developed a clinical research agenda identifying the most pressing clinical questions in AR. Studies conducted by the ARLG may include clinical testing of new drugs to treat multidrug-resistant Gram-negative bacteria, evaluating diagnostic devices in clinical settings, evaluating the effectiveness of new antibacterial stewardship programs, and optimizing treatment regimens to reduce the emergence of resistance. The ARLG is drawing on the creativity of the global research community by inviting concept submissions to identify and address AR priorities. Visit the ARLG website for more information.
Last Updated February 22, 2016